Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease
Akome Biotech Ltd., a subsidiary of Core One Labs Inc. (COOL), has initiated the development of patent-pending drug formulation made of psilocybin and a plant bioactive compound, which is believed to help treat Alzheimer’s Disease. While current Alzheimer’s treatments focus on treating symptoms of the disease, the new drug formulation known as AKO002 aims to treat the underlying cause of the disease by targeting serotonin receptors in the hippocampus. Data mapping reveals that psychedelics like psilocybin have “positive effects in the promotion of neuroplasticity and neurogenesis” and have “potent anti-inflammatory properties”.